Our results provide evidence that miR-302a synergistically increases the sensitivity of AML cells to VP-16 and demonstrate that miR-302a downregulates Rad52 to inhibit tumor growth and chemoresistance, in part via the AKT/Gsk-3β/β-catenin signaling cascade. This evidence concerns the gene RAD52 and acute myeloid leukemia.